SALT LAKE CITY, Oct. 18, 2016 -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that more than 40 of its employees are volunteering to support Project BioEYES, which is a science, technology, engineering and math (STEM) education program designed to teach K-12 students about cell biology, genetics and careers in science. Employees will spend a day in the classroom helping students formulate scientific hypotheses, design experiments and collect data, as well as sharing their own experiences from working in the life sciences.
“The BioEYES program is an ideal opportunity for us to support STEM education in Utah. These programs benefit us all by inspiring students to become tomorrow's innovators and pursue careers in the sciences,” said Mark C. Capone, president and CEO. “Myriad has long been one of the top STEM employers in the state, and we believe that volunteering for programs like this benefits our employees, our communities and our Company.”
Employees attended an orientation session to prepare for their work in the classroom. They learned how to help the students conduct experiments and understand what is entailed in research and the scientific method.
“We are delighted to have the support of Myriad and its employees in educating students about science,” said Judith Neugebauer, Ph.D., BioEYES Utah Program Manager. “These volunteers will help us offer the students opportunities to explore the life sciences by conducting real experiments and sharing their passion for science. Together, we will introduce children to the thrill of scientific discovery.”
For more information, follow us on Twitter via @bioeyes and @MyriadGenetics.
About BioEYES
BioEYES is a K-12 science education program, sponsored by the Department of Pediatrics at the University of Utah that provides active, inquiry-based learning opportunities through the use of live zebrafish. During their program week, students explore both adult and embryonic zebrafish and, by week’s end, they examine the beating heart and blood cells of the zebrafish larvae. The program is designed to incorporate teacher empowerment and provides professional development seminars and a co-teaching experience with trained science consultants, called outreach educators. BioEYES is located at the University of Pennsylvania in Philadelphia, PA; the Carnegie Institution for Science in Baltimore, MD; Monash University in Melbourne, Australia; and the University of Utah in Salt Lake City, UT. Since its inception it has reached over 100,000 students.
About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra, Prolaris and GeneSight are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G
Media Contact: Ron Rogers (801) 584-3065 [email protected] Investor Contact: Scott Gleason (801) 584-1143 [email protected]


Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 



